RecruitingNCT06588205

Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Multicenter, Observational, Retrospective-prospective Study Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Sponsor

Fondazione Italiana Linfomi - ETS

Enrollment

200 participants

Start Date

May 5, 2025

Study Type

OBSERVATIONAL

Conditions

Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Summary

This is a observational, retrospective and prospective study designed to assess the potential correlations between MYC alterations, lymphoma mutational landscape and functional immune contextures in Diffuse Large B-cell Lymphoma or High-Grade B-cell Lymphoma

Eligibility

Min Age: 18 YearsMax Age: 79 Years

Plain Language Summary

Simplified for easier understanding

This is a research study (not a treatment trial) looking at data from patients with aggressive forms of blood cancer called Diffuse Large B Cell Lymphoma (DLBCL) or High-Grade B Cell Lymphoma. Researchers want to understand how a specific gene change (in a gene called MYC) affects outcomes and interacts with the tumor's surrounding environment. **You may be eligible if...** - You were diagnosed with DLBCL or High-Grade B Cell Lymphoma after January 2019 - Your tumor has a MYC gene change (translocation, extra copies, or amplification) confirmed by a lab test called FISH - You received standard curative chemotherapy (such as R-CHOP or R-DA-EPOCH) as your first treatment - You are between 18 and 79 years old - A preserved tissue sample (FFPE block) from your biopsy is available **You may NOT be eligible if...** - Your lymphoma started in the brain, or was diagnosed as Burkitt lymphoma, plasmablastic lymphoma, or primary mediastinal B-cell lymphoma - You only received palliative (comfort-focused) treatment rather than treatment aimed at cure Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(20)

A.O.U. SS. Antonio e Biagio e C. Arrigo - S.C.D.U. Ematologia

Alessandria, Italy

A.O.U. Ospedali Riuniti delle Marche - Clinica di Ematologia

Ancona, Italy

I.R.C.C.S. Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia

Bari, Italy

ASST Spedali Civili - S.C. Ematologia

Brescia, Italy

I.R.C.C.S. Istituto di Candiolo - FPO

Candiolo, Italy

I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncoematologia

Castelfranco Veneto, Italy

ARNAS Garibaldi - U.O.C. Ematologia

Catania, Italy

A.S.T. Macerata - U.O.S.D Ematologia

Civitanova Marche, Italy

Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia

Florence, Italy

ASST Grande Ospedale Metropolitano Niguarda - S.C. Ematologia

Milan, Italy

Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda - S.C. Ematologia

Milan, Italy

A.O.U. di Padova - U.O.C. Ematologia

Padova, Italy

I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncologia 1

Padova, Italy

AUSL Modena sede di Sassuolo - UOSD di Oncologia Area Sud

Sassuolo, Italy

U.O.C. Ematologia - A.O.U. Senese

Siena, Italy

A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia U

Torino, Italy

ULSS 2 Ospedale Ca' Foncello - U.O.C. Ematologia

Treviso, Italy

A.O. Cardinale "G. Panico" - U.O.C Ematologia e Trapianto Midollo Osseo

Tricase, Italy

A.S.U. Giuliano Isontina - S.C. Ematologia

Trieste, Italy

A.O.U.I. di Verona - Ematologia

Verona, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06588205

Related Trials

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT0459464227 locations

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716127 locations

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

NCT034180384 locations

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

NCT044913701 location

Study of CAR-T Therapy in Older Patients

NCT043009981 location